Does VALSARTAN Cause Malignant neoplasm progression? 57 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 57 reports of Malignant neoplasm progression have been filed in association with VALSARTAN (valsartan). This represents 0.3% of all adverse event reports for VALSARTAN.
57
Reports of Malignant neoplasm progression with VALSARTAN
0.3%
of all VALSARTAN reports
22
Deaths
29
Hospitalizations
How Dangerous Is Malignant neoplasm progression From VALSARTAN?
Of the 57 reports, 22 (38.6%) resulted in death, 29 (50.9%) required hospitalization, and 7 (12.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VALSARTAN. However, 57 reports have been filed with the FAERS database.
What Other Side Effects Does VALSARTAN Cause?
Drug ineffective (1,845)
Blood pressure increased (1,682)
Dizziness (1,527)
Headache (1,361)
Hypertension (1,341)
Acute kidney injury (1,301)
Dyspnoea (1,239)
Fatigue (1,156)
Malaise (1,139)
Hypotension (1,032)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which VALSARTAN Alternatives Have Lower Malignant neoplasm progression Risk?
VALSARTAN vs VALTREX
VALSARTAN vs VAMOROLONE
VALSARTAN vs VANCOMYCIN
VALSARTAN vs VANDETANIB
VALSARTAN vs VARDENAFIL